Amarin Co. plc (NASDAQ:AMRN) Short Interest Update

Amarin Co. plc (NASDAQ:AMRN - Get Free Report) saw a significant decline in short interest in April. As of April 15th, there was short interest totalling 629,400 shares, a decline of 94.7% from the March 31st total of 11,970,000 shares. Approximately 3.1% of the company's stock are short sold. Based on an average trading volume of 88,700 shares, the short-interest ratio is presently 7.1 days.

Analyst Upgrades and Downgrades

AMRN has been the subject of several analyst reports. StockNews.com assumed coverage on shares of Amarin in a research note on Wednesday, April 16th. They issued a "sell" rating for the company. The Goldman Sachs Group reduced their price target on Amarin from $20.00 to $7.00 and set a "sell" rating for the company in a research report on Thursday, April 17th.

Amarin Stock Down 6.7 %

Shares of NASDAQ:AMRN traded down $0.75 during trading on Friday, reaching $10.43. The stock had a trading volume of 55,645 shares, compared to its average volume of 73,755. The stock has a fifty day simple moving average of $9.62 and a two-hundred day simple moving average of $10.39. Amarin has a 52 week low of $7.08 and a 52 week high of $20.60. The firm has a market capitalization of $214.17 million, a price-to-earnings ratio of -115.89 and a beta of 1.38.

Amarin (NASDAQ:AMRN - Get Free Report) last announced its earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($1.20) by ($1.20). Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. The firm had revenue of $62.31 million during the quarter, compared to the consensus estimate of $32.37 million. On average, analysts forecast that Amarin will post -0.15 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AMRN. New York State Common Retirement Fund bought a new position in Amarin during the fourth quarter worth $68,000. Waterfront Wealth Inc. increased its holdings in shares of Amarin by 181.4% during the 4th quarter. Waterfront Wealth Inc. now owns 2,481,766 shares of the biopharmaceutical company's stock worth $1,204,000 after purchasing an additional 1,599,956 shares during the period. Arkfeld Wealth Strategies L.L.C. raised its position in shares of Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 20,000 shares during the last quarter. LCM Capital Management Inc lifted its stake in shares of Amarin by 3.1% in the fourth quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company's stock valued at $407,000 after buying an additional 25,100 shares during the period. Finally, Stonepine Capital Management LLC acquired a new stake in Amarin during the fourth quarter worth about $55,000. 22.25% of the stock is currently owned by institutional investors and hedge funds.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.